Skip to main content
Zelluna ASA logo

Zelluna ASA — Investor Relations & Filings

Ticker · ULTI ISIN · NO0010851603 LEI · 254900B4VALJZR9TL744 OL Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2022-11-10 Director's Dealing
Country NO Norway
Listing OL ULTI

About Zelluna ASA

https://www.zelluna.com/

Zelluna ASA is a cell therapy company pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company's proprietary TCR-NK platform is designed to combine the high-precision targeting of TCRs with the potent, innate anti-tumor activity of NK cells. This approach aims to overcome the challenges associated with treating solid tumors. Zelluna is focused on creating a new generation of allogeneic, "off-the-shelf" cell therapies. The mission is to deliver transformative and potentially curative treatments for patients with advanced solid cancers, addressing a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing Classification · 100% confidence The document explicitly states it is a 'Mandatory notification of trade by primary insider' concerning a purchase of shares by a closely associated party of the board chair. This directly corresponds to the definition of Director's Dealing (insider trades) as per the provided classifications. The filing type code for this is DIRS.
2022-11-10 English
Ultimovacs ASA Reports Third Quarter 2022 Financial Results and Provides General Business Update
Investor Presentation Classification · 95% confidence The document is titled 'Third Quarter 2022 Results' and is explicitly identified as a presentation by Ultimovacs ASA. It contains detailed operational updates, clinical trial progress, and financial tables (income statement and cash position) for the third quarter of 2022. While it is a presentation, it serves as the primary vehicle for communicating the quarterly financial and operational performance to investors, fitting the definition of an Investor Presentation (IP) which often accompanies or serves as the core of quarterly reporting materials. Q3 2022
2022-11-10 English
Ultimovacs ASA Reports Third Quarter 2022 Financial Results and Provides General Business Update
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Third Quarter Report' for Ultimovacs ASA and contains comprehensive financial statements (income statement, cash flow, balance sheet data), operational updates, and management commentary for the period ending September 30, 2022. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q3 2022
2022-11-10 English
Ultimovacs ASA Reports Third Quarter 2022 Financial Results and Provides General Business Update
Earnings Release Classification · 100% confidence The document is explicitly titled "Ultimovacs ASA Reports Third Quarter 2022 Financial Results and Provides General Business Update." It contains detailed financial figures for Q3-22 (operating expenses, total loss, cash flow) and extensive clinical trial updates typical of a periodic report. Since it covers a period shorter than a year ("Third Quarter 2022") and provides comprehensive financial details, it fits the definition of an Interim / Quarterly Report (IR). Although it mentions the quarterly report and presentation will be published, the text provided *is* the content summarizing those results, not just a brief announcement of publication, making IR more appropriate than RPA. Q3 2022
2022-11-10 English
Ultimovacs ASA: Invitation to Third quarter 2022 results webcast presentation
Report Publication Announcement Classification · 98% confidence The document is titled 'Invitation to Third quarter 2022 results webcast presentation' and explicitly invites stakeholders to a webcast presentation of the Q3 2022 results scheduled for November 10, 2022. It states that the 'report and presentation will be available on the company website from 08:00 CET the same day.' Since the document is very short (1180 characters) and its primary function is to announce the upcoming release and presentation of the actual financial results (which are not contained within this text), it fits the definition of a Report Publication Announcement (RPA). It is not the Earnings Release (ER) itself, nor the Interim Report (IR).
2022-11-03 English
Ultimovacs Announces First Patient Randomized in Phase II LUNGVAC Trial of UV1 in Non-Small Cell Lung Cancer (NSCLC)
Regulatory Filings Classification · 97% confidence The document is a press release titled "Ultimovacs Announces First Patient Randomized in Phase II LUNGVAC Trial...". It details clinical trial progress, combination therapies, endpoints, and provides company background. This type of announcement, focusing on operational or clinical milestones rather than comprehensive financial results (like 10-K or IR) or management changes (MANG), typically falls under general regulatory announcements or investor news. Since it is not a formal financial report, a specific financing event, or a management/director transaction, and it is a direct announcement of a significant operational event, it best fits the general 'Regulatory Filings' (RNS) category, which serves as a broad category for non-standard regulatory disclosures, or potentially a general Investor Relations announcement. Given the context of a clinical trial update, RNS is the most appropriate general regulatory disclosure category.
2022-10-25 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.